scholarly journals Hemolytic uremic syndrome caused by sea anemone sting: a case report

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
A Young Kim ◽  
Kyu Hyang Cho ◽  
Seok Hui Kang ◽  
Jong Won Park ◽  
Jun Young Do ◽  
...  

Abstract Background Some sea anemone toxins cause renal injuries resembling hemolytic uremic syndrome (HUS). To date, only a few cases of HUS caused by sea anemone stings have been reported. In this case report, we have described an HUS case caused by a sea anemone sting. Case presentation In November 2019, a 37-year-old man with no underlying disease was admitted to our hospital. He presented with intense pain, a rash on, and swelling in his right thigh. Two days prior, he had been stung by a sea anemone while scuba diving in Cebu, Philippines. His blood tests revealed renal dysfunction, and his platelet count was normal. However, on day three, the platelet count decreased rapidly. His blood haptoglobin level decreased, and schistocytes were identified on the peripheral blood smear. We suspected thrombotic microangiopathy and started the conventional treatment, comprising hemodialysis, blood transfusion, and antibiotic administration. ADAMTS-13 and genetic test results associated with atypical HUS were normal. Therefore, the patient was diagnosed with HUS caused by a sea anemone toxin. Conclusions HUS caused by a sea anemone toxin is rare, but it is a serious medical disease. Clinicians should consider HUS in patients with such clinical presentations, and they should make prompt treatment-related decisions.

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
A. Young Kim ◽  
Kyu Hyang Cho ◽  
Seok Hui Kang ◽  
Jong Won Park ◽  
Jun Young Do ◽  
...  

Nephron ◽  
2017 ◽  
Vol 138 (4) ◽  
pp. 324-327 ◽  
Author(s):  
Hironori Nakamura ◽  
Mariko Anayama ◽  
Mutsuki Makino ◽  
Yasushi Makino ◽  
Katsuhiko Tamura ◽  
...  

2014 ◽  
Vol 8 ◽  
pp. BCBCR.S14920
Author(s):  
Victor C. Kok ◽  
Sheng-Chung Wu ◽  
Chien-Kuang Lee

Sequential palliative chemotherapy for metastatic breast cancer incorporating weekly gemcitabine administered as three-weeks-on, one-week-off schedule is widely adopted throughout the East Asia region. Hemolytic-uremic syndrome (HUS) associated with weekly gemcitabine for a breast cancer patient is extremely rare. We report here a case of 43-year-old woman with metastatic breast cancer who received weekly gemcitabine as a third-line palliative chemotherapy for her disease. She developed HUS after a cumulative dose of 11,000 mg/m2 gemcitabine, evidenced by microangiopathic hemolytic anemia (MAHA) with schistocytes seen in peripheral blood smear, decreased haptoglobin level (<0.29 mmol/L), thrombocytopenia, negative direct Coombs test, and acute kidney injury. Owing to the ease of administration of weekly gemcitabine, gemcitabine-induced thrombocytopenia, multifactorial anemia in metastatic breast cancer, and possibility of cancer progression, HUS could have gone unnoticed. Breast cancer oncologist should be cognizant of this rare HUS even during weekly gemcitabine treatment.


2017 ◽  
Vol 07 (02) ◽  
Author(s):  
Villalba NL ◽  
Merzouki T ◽  
Gonzalez NS ◽  
Ortiz MBA ◽  
Kechida M ◽  
...  

2018 ◽  
Vol 01 (02) ◽  
pp. 21-27
Author(s):  
N.A. Zharkin ◽  
M.E. Statsenko ◽  
M.M. Stazharova ◽  
N.A. Burova ◽  
S.A. Prokhvatilov ◽  
...  

2019 ◽  
Vol 10 (12) ◽  
pp. 343-344
Author(s):  
Mae-Lan Winchester ◽  
Ryan Platzbecker ◽  
Megan McMahon ◽  
Marc Parrish

Sign in / Sign up

Export Citation Format

Share Document